Scrub-a-Dub-Dub: FTC is Cleansing the Orange Book of Device Patents
FDA Law Blog
JUNE 13, 2024
FTC, deep in its foray into the Orange Book, filed an Amicus Brief in the case arguing that the patents do not claim any FDA-approved drug.
Containment Drug Delivery Drug Delivery Systems FDA Approval 
116 
Five key drug discovery deals of summer 2023
Drug Discovery World
AUGUST 9, 2023
The new acquisition gives Biogen rights to Reata’s portfolio of products for neurological diseases, including the FDA-approved Skyclarys (omaveloxolone), the only approved treatment for Friedreich’s ataxia (FA) in the United States.
Drugs Companies Clap Back at Congress…Then Get Sued
FDA Law Blog
MARCH 12, 2024
It’s difficult to conclude from these statements, as FTC and Congress appear to have, that device patents categorically shouldn’t be listed in the Orange Book.
Let's personalize your content